نتایج جستجو برای: overall response rate orr

تعداد نتایج: 2165667  

Journal: :Frontiers in Pharmacology 2023

Introduction: Treatment of relapsed or refractory acute myeloid leukemia (R/R AML) and sarcoma (MS) has presented challenges for decades. Studies on selinexor in combination with various standard intensive chemotherapy regimens the treatment R/R AML have demonstrated promising results. This study aimed to evaluate efficacy safety chemotherapy-free low-dose MS patients. Methods: Ten patients who...

Journal: :Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009
David P Steensma Maria R Baer James L Slack Rena Buckstein Lucy A Godley Guillermo Garcia-Manero Maher Albitar Julie S Larsen Sujata Arora Michael T Cullen Hagop Kantarjian

PURPOSE Decitabine, a DNA-targeted hypomethylating agent, is approved by the United States Food and Drug Administration for treatment of patients with myelodysplastic syndromes (MDS) on a schedule of 15 mg/m(2) administered via intravenous (IV) infusion every 8 hours for 3 days. This study assessed the efficacy and safety of an alternative dosing regimen administered on an outpatient basis in a...

2016
Emilie Reboursiere Fabien Le Bras Charles Herbaux Emmanuel Gyan Aline Clavert Franck Morschhauser Sandra Malak David Sibon Florence Broussais Thorsten Braun Luc-Matthieu Fornecker Reda Garidi Sabine Tricot Roch Houot Bertrand Joly Wajed Abarah Bachra Choufi Anne-Dominique Pham Anne-Claire Gac Christophe Fruchart Emilie Marin Violaine Safar Anne Parcelier Hervé Maisonneuve Emmanuel Bachy Guillaume Cartron Arnaud Jaccard Olivier Tournilhac Cédric Rossi Luciane Schirmer Jean-Alain Martignoles Philippe Gaulard Hervé Tilly Gandhi Damaj

Peripheral T-cell lymphoma (PTCL) is a group of diseases with poor outcome and few therapeutic options. We aimed to assess the efficacy of bendamustine in real life cohort of patients.Between November 2009 and March 2015, 138 PTCL patients were treated with bendamustine in 27 centers. Population median age was 64 (28-89) years with male/female ratio of 1.4. There were mainly angio-immunoblastic...

Journal: :Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016
Sai-Hong Ignatius Ou Jin Seok Ahn Luigi De Petris Ramaswamy Govindan James Chih-Hsin Yang Brett Hughes Hervé Lena Denis Moro-Sibilot Alessandra Bearz Santiago Viteri Ramirez Tarek Mekhail Alexander Spira Walter Bordogna Bogdana Balas Peter N Morcos Annabelle Monnet Ali Zeaiter Dong-Wan Kim

PURPOSE Crizotinib confers improved progression-free survival compared with chemotherapy in anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC), but progression invariably occurs. We investigated the efficacy and safety of alectinib, a potent and selective ALK inhibitor with excellent CNS penetration, in patients with crizotinib-refractory ALK-positive NSCLC. PATIEN...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2006
R Baz E Walker M A Karam T K Choueiri R A Jawde K Bruening J Reed B Faiman Y Ellis C Brand G Srkalovic S Andresen R Knight J Zeldis M A Hussein

BACKGROUND Lenalidomide is active and well tolerated in relapsed and refractory multiple myeloma. We conducted a phase I/II trial of the combination of lenalidomide and chemotherapy to evaluate the safety and efficacy of the combination. METHODS The 62 patients enrolled received liposomal doxorubicin 40 mg/m(2) i.v. and vincristine 2 mg i.v. on day 1, dexamethasone 40 mg p.o. on days 1-4 (DVd...

2017
Peipei Xing Jin Zhang Zhao Yan Gang Zhao Xubin Li Guowen Wang Yun Yang Jun Zhao Ruwei Xing Sheng Teng Yulin Ma Zhichao Liao Zhiwu Ren Chao Zhang Xiuxin Han Wei Zhang Kexin Chen Ping Wang Jilong Yang

PURPOSE This retrospective case-series study evaluated efficacy and safety of Endostar combined with chemotherapy in the treatment of advanced bone and soft tissue sarcomas in stage IV. MATERIALS AND METHODS Forty-seven patients diagnosed with stage IV bone and soft tissue sarcomas and treated with chemotherapy in Tianjin Medical University Cancer Institute & Hospital were reviewed. Of these ...

2015
Zhengzi Qian Zheng Song Huilai Zhang Xianhuo Wang Jing Zhao Huaqing Wang

T-cell lymphoma (TCL) is resistant to conventional chemotherapy. We retrospectively evaluated the therapeutic efficiency and toxicity of gemcitabine, navelbine, and doxorubicin (GND) in patients with refractory or relapsed TCL. From 2002 to 2012, 69 patients with refractory or relapsed TCL received GND treatment in our hospital. The treatment protocol comprised gemcitabine (800 mg/m(2), group 1...

2016
Tsutomu Takashima Shinya Tokunaga Seika Tei Shigehiko Nishimura Hidemi Kawajiri Shinichiro Kashiwagi Shigehito Yamagata Satoru Noda Takeo Nishimori Yoko Mizuyama Takeshi Sunami Kenji Tezuka Katsumi Ikeda Yoshinari Ogawa Naoyoshi Onoda Tetsuro Ishikawa Shinzoh Kudoh Minoru Takada Kosei Hirakawa

The treatment goals for metastatic breast cancer (MBC) are prolonging survival and improving the quality of life. Eribulin, a non-taxane tubulin inhibitor, demonstrated improved survival in previous studies and also showed mild toxicity when used in late-line therapy for MBC. We conducted a phase II study to investigate the efficacy of eribulin mesylate as the first-line chemotherapy for human ...

2017
Yan Liu Zhong Zheng Qixin Zhang Xinling Zhou Yikuan Feng Anquan Yan

PURPOSE To systematically investigate the efficacy and safety of the combination of FOLFOX (oxaliplatin, 5-fluorouracil, and leucovorin) regimen and cocultured dendritic cells and cytokine-induced killer cells (DC-CIK) immunotherapy for the treatment of colorectal cancer (CRC). METHODS Publications reporting the clinical trials' responses or safety of FOLFOX regimen combined with DC-CIK immun...

Journal: :PloS one 2016
Yuan Yuan Zhou Zhi Gang Hu Fan Jun Zeng Jiao Han

BACKGROUND Evidence on the benefits of combining cyclooxygenase-2 inhibitor (COX-2) in treating non-small cell lung cancer (NSCLC) is still controversial. We investigated the efficacy and safety profile of cyclooxygenase-2 inhibitors in treating NSCLC. METHODS The first meta-analysis of eligible studies was performed to assess the effect of COX-2 inhibitors for patients with NSCLC on the over...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید